ImmunoPrecise Antibodies Ltd. has announced new findings from an expanded study demonstrating the effectiveness of its LENSai™ Immunogenicity Screening in predicting Anti-Drug-Antibody $(ADA.AU)$ risk for therapeutic proteins before clinical trials. The study analyzed 217 marketed and clinical-stage antibodies, making it the largest public ADA dataset to predict immunogenicity risk. LENSai™ offers a significant advantage by enabling rapid candidate triage using a single composite score system that accurately flags high-risk candidates. The proprietary HYFT-powered engine evaluates nearly 900 HLA variants and performs a whole-proteome humanness scan, providing detailed immunogenicity scanning. These results have already been presented, showcasing the platform's ability to potentially shorten pre-clinical cycles and reduce costs.